SLC5A2 and Nephropathy: In patients with type 2 diabetes treated with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, cardiovascular outcome and death as well as hospitalization for heart failure decreased [7] and the progression of kidney disease (as defined by incident or worsening of nephropathy) was attenuated [8].